Page last updated: 2024-08-21

alpha-aminopyridine and Minimal Disease, Residual

alpha-aminopyridine has been researched along with Minimal Disease, Residual in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Bajciova, V; Jezova, M; Kanderova, V; Krenova, Z; Kyr, M; Lakka Klement, G; Merta, T; Mudry, P; Noskova, K; Palova, H; Pokorna, P; Slaby, O; Sterba, J; Valik, D; Vasikova, A; Zdrazilova Dubska, L1
Estey, EH; Percival, MM1

Reviews

1 review(s) available for alpha-aminopyridine and Minimal Disease, Residual

ArticleYear
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
    Cancer, 2019, Sep-15, Volume: 125, Issue:18

    Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles

2019

Other Studies

1 other study(ies) available for alpha-aminopyridine and Minimal Disease, Residual

ArticleYear
Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing.
    JCO precision oncology, 2022, Volume: 6

    Topics: Aminopyridines; Humans; Lactams; Lactams, Macrocyclic; Lymphoma, Large-Cell, Anaplastic; Neoplasm, Residual; Pyrazoles

2022